Treatment of deep venous thrombosis with low molecular weight heparin in pediatric cancer patients: Safety and efficacy

Blood Coagulation and Fibrinolysis

Volumn 20, Issue 7, 2009, Pages 583-589

  Tousovska, Katerina ^a   Zapletal, Ondrej ^b   Skotakova, Jarmila ^c   Bukac, Josef ^d   Sterba, Jaroslav ^c  

^a UNIVERSITY HOSPITAL HRADEC KRALOVE   (Czech Republic)

^b Department of Clinical Hematology ^*

^c UNIVERSITY HOSPITAL BRNO   (Czech Republic)

^d CHARLES UNIVERSITY   (Czech Republic)

Author keywords

Cancer; Children; Low molecular weight heparin; Monitoring; Thrombosis; Treatment

Indexed keywords

DALTEPARIN; ENOXAPARIN; LOW MOLECULAR WEIGHT HEPARIN;

ADOLESCENT; ADULT; ARTICLE; BLEEDING; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLOW UP; HUMAN; INFANT; MALE; PEDIATRICS; POSTTHROMBOSIS SYNDROME; PRESCHOOL CHILD; PRIORITY JOURNAL; PROSPECTIVE STUDY; RISK FACTOR; SCHOOL CHILD; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; VASCULAR PATENCY; ADVERSE DRUG REACTION; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; NEOPLASMS; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADOLESCENT; CHILD; CHILD, PRESCHOOL; DRUG-RELATED SIDE EFFECTS AND ADVERSE REACTIONS; FOLLOW-UP STUDIES; HEMORRHAGE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; INFANT; NEOPLASMS; POSTTHROMBOTIC SYNDROME; THROMBOCYTOPENIA; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 70349795929     PISSN: 09575235     EISSN: None     Source Type: Journal    
DOI: 10.1097/MBC.0b013e32832ff577     Document Type: Article

References (41)

1. Athale UA, Chan A. Thromboembolic complications in pediatric hematology malignancies. Sem Thromb Hemost 2007; 33:416-426. (Pubitemid 46878114)
2. Monagle P, Chan A, Massicotte P, Chalmers E, Michelson A. Antithrombotic therapy in children: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 2004; 126:645-687.
3. Andrew M, David M, Adams M, Kaiser A, Anderson R, Barnard D, et al. Venous Thrombembolic Complications (VTE) in Children: First Analyses of the Canadian Registry of VTE. Blood 1994; 83:1251-1257.
4. Caruso V, Di Castelnuovo A, Storti S, Mariani G, de Gaetano G, et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108:2216-2222.
5. Nowak-Göttl U, Kosch A, Schlegel N. Thromboembolism in newborns, infants and children. Thromb Haemost 2001; 86:464-474.
6. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukaemia. Part I: Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res 2003; 111:125-131.
7. Mitchell L, Andrew M, Hanna K, Abshire T, Halton J, Wu J, et al. Trend to efficacy and safety using antithrombin concentrate in prevention of thrombosis in children receiving L-asparaginase for acute lymphoblastic leukaemia. Thromb Haemost 2003; 90:235-244.
8. Athale U, Cox S, Siciliano S, Chan A. Thrombembolism in children with sarcoma. Pediatr Blood Cancer 2007; 49:171-176.
9. Bajzar L, Chan AK, Massicotte P, Mitchell L. Thrombosis in children with malignancy. Curr Opin Pediatr 2006; 18:1-9.
10. Lee AY. Venous thromboembolism and cancer: new insights and therapy. Hematology 2005;450-453.
11. Kuhle S, Massicotte P, Chan A, Adams M, Abdolelli M, de Veber G, et al. Systemic thromboembolism in children. Data from the I-800-NO CLOTS consultation Service. Thromb Haemost 2004; 92:722-728.
12. Nowak-Göttl U, Heinecke A, von Kries R, Nurnberger W, Munchow N, Junker R. Thrombotic events revisited in children with acute lymphoblastic leukaemia. Impact of concomitant Escherichia coli asparaginase/ prednisone administration. Thromb Res 2002; 103:165-172.
13. Prandoni P. Acquired risk factors for venous thromboembolism in medical patients. Hematology 2005:458-461.
14. Kahn S. The postthrombotic syndrome: progress and pitfalls. Br J Haematol 2006; 134:357-365.
15. Goldenberg NA, Durham JD, Knapp-Clevenger R, Manco-Johnson M. A thrombolytic regimen for high-risk deep venous thrombosis may substantially reduce the risk of postthrombotic syndrome in children. Blood 2007; 110:45-53.
16. Beltrametti C, D'Angelo A. Normalization rates of compression ultrasonography in patients with a first episode of deep vein thrombosis of the lower limbs: association with recurrence and new thrombosis. Haematologica 2002; 87:515-552.
17. Prandoni P, Lensing AWA, Prins MH, Bernardi E, Marchiori A, Bagatella P, et al. Residual vein thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Inter Med 2002; 137:955-960.
18. Goldenberg NA, Knapp-Clevenger R, Manco-Johnson MJ. Elevated plasma factor VIII and D-dimer levels as predictors of poor outcomes of thrombosis in children. N Engl J Med 2004; 351:1081-1088.
19. Kuhle S, Koloshuk B, Marzintotto V, Bauman M, Massicotte P, Andrew M, et al. A cross sectional study evaluating postthrombotic syndrome in children. Thromb Res 2003; 111:227-233.
20. Schobess R, Düring C, Bidlingmaier C, Heinecke A, Merkel N, Nowak-Göttl U. Long-term safety and efficacy on childhood venous thrombosis treated with a low molecular Wight heparin: an open-label pilot study of once-daily versus twice daily enoxaparin administration. Haematologica 2006; 91:1701-1704.
21. Massicotte P. Low molecular-weight heparin therapy in children. J Pediatr Hematol Oncol 2001; 23:189-194.
22. Boneu B, de Moerloose P. How and when to monitor a patient treated with low molecular weight heparin. Sem Thromb Hemost 2001; 27:519-522.
23. Gouin-Thibault I, Pautas E, Siguret V. Safety profile of different lowmolecular weight heparins used at therapeutic dose. Drug Safety 2005; 4:333-349.
24. Manco-Johnson MJ. How I treat venous thrombosis in children. Blood 2006; 107:21-29.
25. Nohe N, Flemmer A, Rümler R, Praun M, Auberger K. The low molecular weight heparin dalteparin for prophylaxis and therapy of thrombosis in childhood: a report on 48 cases. Eur J Pediatr 1999; 158 (Suppl 3): S134-S139.
26. Merkel N,Günther G, Schobess R. Long-term treatment of thrombosis with enoxaparin in pediatric and adolescent patients. Acta Haematol 2006; 115:230-236.
27. Hulot JS, Vantelon C, Urien S, Bouzamondo A, Mahé I, Ankri A, et al. Effect of renal function on the pharmacokinetics of enoxaparin and consequences on dose adjustment. Drug Monit 2004; 26:305-310.
28. Revel-Vilk S, Sharathkumar A, Massicotte P, Marzintotto V, Daneman A, Dix D, et al. Natural history of arterial and venous thrombosis in children treated with low molecular weight heparin: a longitudinal study by ultrasound. J Thromb Haemost 2003; 2:42-46.
29. Stine KC, Saylors RS, Saccente CZ, Becton DL. Treatment of deep vein thrombosis with enoxaparin in pediatric cancer patients receiving chemotherapy. Clin Appl Thromb Haemost 2002; 13:161-165.
30. Elhasid R, Lanir N, Sharon R, Weyl Ben Arush M, Levin C, Postovsky S, et al. Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukaemia. Blood Coagul Fibrinolysis 2001; 12:367-370. (Pubitemid 32730495)
31. Prandoni P. How I treat venous thromboembolism in patients with cancer. Blood 2005; 106:4027-4032.
32. Ibrahim RB, Peres E, Dansey R, Abidi MH, Abella EM, Gumma MM, et al. Safety of low-dose low-molecular weight heparins in thrombocytopenic stem cell transplantation patients: a case series and review of the literature. Bone Marrow Transplant 2005; 35:1071-1077.
33. Giordano P, Del Vecchio GC, Saracco P, Zecca M, Molinari AC, DeMattia D, et al. A practical approach to diagnosis and treatment of symptomatic thromboembolic events in children with acute lymphoblastic leukemia: recommendations of the 'coagulation defects' AEIOP Working Group. Recent Patents Cardiovasc Drug Discov 2007; 2:53-62.
34. Chong BH, Szu-Hee L. Management of thromboembolism in hematologic malignancies. Sem Thromb Hemost 2007; 33:435-447.
35. Imberti D, Agneli G, Ageno W, Moia M, Plareti G, Pistelli R, et al. Clinical characteristics and management of cancer-associated acute venous thromboembolism: findings from the MASTER registry. Haematologica 2008; 93:273-278.
36. Ruud E, Holmstrom H, De Lange C, Hogstad EM, Wesenberg F. Low dose warfarin for the prevention of central line-associated thrombosis in children with malignancies: a randomized, controlled study. Acta Paediatr 2006; 95:1053-1059.
37. Rosenbloom D, Ginsberg JS. Arguments against monitoring levels of antifactor Xa in conjunction with low-molecular-weight heparin therapy. Can J Hosp Pharm 2002; 55:15-19.
38. Ho SH, Wu JK, Hamilton DP, Dix DB, Wadsworth LD. An assessment of published pediatric dosage guidelines for enoxaparin. A retrospective review. J Pediatr Hematol Oncol 2004; 26:561-566.
39. Dix D, Andrew M, Marzintotto V, Charpentier K, Bridge S, Monagle P, et al. The use of low molecular weight heparin in pediatric patients: a prospective cohort study. J Pediatr 2000; 136:439-445.
40. Alhenc-Gelas M, Jestin-Le Guernic C, Vitoux JF, Kher A, Aiach M, Fiessinger JN. Adjusted versus fixed doses of the low-molecular-weight heparin Fragmin in the treatment of deep vein thrombosis. Fragmin Study Group. Thromb Haemost 1994; 71:698-702.
41. Nowak-Göttl U, Junker R, Kreuz W, von Eckardstein A, Nohe N, Schobess R, et al. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 87:858-862. (Pubitemid 32154265)